Sun Pharma Enters Definitive Agreement to Acquire Organon
Sun Pharmaceutical Industries Limited and Organon & Co. have entered into a definitive agreement that marks one of the most significant consolidation moves in the global pharmaceutical sector in recent years. Under the terms of the deal, Sun Pharma will acquire all outstanding shares of Organon in an all-cash transaction valued at approximately $11.75 billion, offering shareholders $14.00 per share. The acquisition reflects a bold strategic expansion by Sun Pharma as it seeks to strengthen its global footprint, diversify its therapeutic portfolio, and accelerate its transition toward a more innovation-driven business model.
Organon, which was established in 2021 following its spin-off from Merck & Co. (known as MSD outside the United States and Canada), has quickly built a strong identity as a global healthcare company with a particular focus on women’s health. The company’s portfolio spans more than 70 products across key therapeutic areas, including women’s health, biosimilars, and general medicines. These products are commercialized across approximately 140 countries, with major markets including the United States, Europe, China, Canada, and Brazil.
A key strength of Organon lies in its well-established global infrastructure, which includes six manufacturing facilities located across the European Union and various emerging markets. This extensive footprint has enabled the company to build strong relationships with healthcare professionals, regulators, and patients worldwide. Organon’s dual focus on women’s health and general medicines underscores its commitment to improving access to essential treatments while maintaining affordability—a mission that aligns closely with Sun Pharma’s own global healthcare ambitions.
The acquisition is strategically aligned with Sun Pharma’s long-term vision of expanding its Innovative Medicines segment while reinforcing its leadership in established brands and branded generics. By integrating Organon’s assets, Sun Pharma is expected to significantly enhance its capabilities in several high-growth segments, including biosimilars, where the combined entity is projected to emerge as a top-10 global player.
In addition to strengthening its position in biosimilars, the transaction is set to elevate Sun Pharma’s standing in the global pharmaceutical hierarchy. Upon completion, the combined company is expected to rank among the top 25 pharmaceutical companies worldwide, with pro forma revenues estimated at $12.4 billion. The deal also positions Sun Pharma as a leading force in the established brands and branded generics segment, while simultaneously increasing the contribution of innovative medicines to approximately 27% of total revenue.
One of the most transformative aspects of the acquisition is Sun Pharma’s entry into the global women’s health market at scale. Organon’s strong presence in this space is expected to make the combined entity one of the top three companies globally in women’s health, creating a robust commercial platform for future product launches and pipeline expansion. This move not only diversifies Sun Pharma’s therapeutic focus but also opens new avenues for growth in a segment that has historically been underrepresented in pharmaceutical innovation.
The geographic reach of the combined organization will also expand significantly, with operations spanning approximately 150 countries. Notably, the company will have a strong presence in 18 key markets, each generating more than $100 million in annual revenue. This broad international footprint is expected to enhance market access, improve supply chain resilience, and create opportunities for cross-selling and portfolio optimization.
From a financial perspective, the acquisition is anticipated to substantially strengthen Sun Pharma’s cash generation capabilities. The combined entity’s EBITDA and operating cash flow are projected to nearly double, providing a solid foundation for deleveraging. Following the transaction, the company’s net debt-to-EBITDA ratio is expected to stand at approximately 2.3x, with a clear pathway toward reduction through enhanced earnings and disciplined capital management.
The transaction has received approval from the boards of directors of both companies and is subject to customary closing conditions, including regulatory clearances and approval from Organon’s shareholders. The deal is currently expected to close in early 2027.
Commenting on the acquisition, Dilip Shanghvi highlighted the strategic importance of the transaction in advancing the company’s mission of “Reaching People and Touching Lives.” He emphasized that Organon’s complementary portfolio, capabilities, and global reach would help create a more diversified and resilient organization. Shanghvi also expressed confidence in the long-term growth potential that could be unlocked by combining the strengths of both companies.
Kirti Ganorkar described the deal as a logical progression in Sun Pharma’s global expansion strategy. He noted that the combined entity would be better positioned to serve as a partner of choice for acquiring and launching new products. Ganorkar also outlined key priorities following the acquisition, including ensuring business continuity, executing a disciplined integration process, and delivering sustainable value creation. He pointed to significant synergy opportunities, particularly in terms of revenue growth and operational efficiencies, which are expected to materialize over the coming years.
From Organon’s perspective, Carrie Cox stated that the agreement followed a comprehensive evaluation of strategic alternatives. She emphasized that the all-cash transaction delivers immediate and compelling value to Organon’s shareholders while also ensuring that the company’s mission and operations will be supported under Sun Pharma’s ownership. Cox expressed confidence that Sun Pharma’s scale and capabilities would enable Organon to continue delivering impactful healthcare solutions to patients worldwide.
The structure of the transaction involves Sun Pharma acquiring 100% of Organon’s outstanding shares through a merger with a subsidiary of Sun Pharma, with Organon continuing as the surviving entity. To finance the acquisition, Sun Pharma plans to utilize a combination of existing cash reserves and committed funding from leading financial institutions.
Organon’s financial performance provides additional context for the scale of the transaction. For the fiscal year ending December 31, 2025, the company reported revenues of $6.2 billion and an adjusted EBITDA of $1.9 billion. At the same time, Organon carried total debt of $8.6 billion and held a cash balance of $574 million. The company has also recently strengthened its liquidity position through the divestiture of a product, generating upfront proceeds of $440 million.
A number of prominent financial and legal advisors are supporting the transaction. J.P. Morgan Securities LLC and Jefferies LLC are serving as financial advisors to Sun Pharma, while White & Case LLP and AZB & Partners are providing legal counsel. Financing for the deal is being arranged by institutions including Citigroup Global Markets Asia Ltd., JPMorgan Chase Bank, and MUFG Bank.
On Organon’s side, Morgan Stanley is acting as lead financial advisor, alongside Goldman Sachs, with legal counsel provided by Sullivan & Cromwell LLP and Cyril Amarchand Mangaldas.
Overall, the acquisition represents a transformative step for Sun Pharma, significantly enhancing its global scale, diversifying its portfolio, and strengthening its position across multiple high-value therapeutic areas. By combining Organon’s established presence in women’s health and biosimilars with Sun Pharma’s expertise in generics and specialty medicines, the deal has the potential to reshape the competitive landscape of the global pharmaceutical industry while delivering long-term value for stakeholders and improved access to medicines for patients worldwide.
About Sun Pharmaceutical Industries Limited (CIN – L24230GJ1993PLC019050)
Sun Pharma is the world’s leading specialty generics company with a presence in Innovative Medicines, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun’s high growth Global Innovative Medicines portfolio spans innovative products in dermatology, ophthalmology, and oncodermatology and accounts for about 20% of company sales.
The company’s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across five continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. “For further information, please visit www.sunpharma.com and follow us on LinkedIn & X (Formerly Twitter).”
About Organon & Co.
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.
Source Link:https://www.businesswire.com/
